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Background: Reducing treatment delay improves outcomes in breast cancer. The aim of this study was to
determine factors influencing patient- and system-related delays in commencing breast cancer treatment in
different countries. Methods: A total of 6588 female breast cancer patients from 12 countries were surveyed.
Total delay time was determined as the sum of the patient-related delay time (time between onset of the first
symptoms and the first medical visit) and system-related delay time (time between the first medical visit and the
start of therapy). Results: The average patient-related delay time and total delay time were 4.7 (range: 3.4–6.2)
weeks and 14.4 (range: 11.5–29.4) weeks, respectively. Longer patient-related delay times were associated with
distrust and disregard, and shorter patient-related delay times were associated with fear of breast cancer,
practicing self-examination, higher education level, being employed, having support from friends and family
and living in big cities. The average system-related delay time was 11.1 (range: 8.3–24.7) weeks. Cancer
diagnosis made by an oncologist versus another physician, higher education level, older age, family history of
female cancers and having a breast lump as the first cancer sign were associated with shorter system-related delay
times. Longer patient-related delay times and higher levels of distrust and disregard were predictors of longer
system-related delay times. Conclusions: The delay in diagnosis and treatment of breast cancer remains a serious
problem. Several psychological and behavioural patient attributes strongly determine both patient-related delay
time and system-related delay time, but their strength is different in particular countries.
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Introduction
Breast cancer (BC) is one of the most common causes of cancerdeaths in women. Within the past decade, BC mortality has been
decreasing in developed countries.1 In contrast, owing to lack of
organized population-based screening programmes, lower BC
awareness and poorer infrastructure, this has not been achieved in
many low- and middle-income countries.2,3 Consequently, the BC
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burden will remain a major health problem globally within the next
decades.
Delays in diagnosis and treatment of BC may seriously impact
survival.4,5 Treatment of BCs diagnosed at a later stage is also
associated with higher morbidity, due to more aggressive and
disfiguring approaches, and is more expensive. Thus, reducing
these delays is believed to be of high importance. The delay in
cancer care delivery may be categorized into patient-, physician-
and system-related factors.6 Although factors associated with a
delay in BC care have been well described,7 the data on their
relative impact and on mitigation strategies are scarce. Most of the
studies performed so far have dealt with patient-related delays,
whereas few addressed system-related delays.8 The aim of the
present study was to analyse the differences in time to diagnosis and
treatment initiation in BC patients across a number of low- and
middle-income countries, and to identify factors related to delays.
Methods
Patients
This study is based on a questionnaire survey conducted in 2011 in
12 countries. The countries were selected to represent a wide
spectrum of different socioeconomic, geographical and cultural
settings. The target population was defined as female BC patients
undergoing treatment within 6 months preceding the survey, which
for most countries spanned a period of 2–3 months in 2011. The
selection of respondents followed the cluster sampling technique,
conducted separately in each country. Considering the number of
BC patients treated in 2010, a pre-specified number of oncology
centres (ranging from 4 in Slovakia to 13 in Turkey) were
randomly selected for the survey.
Questionnaire
The basic study questionnaire (originally developed in English) was
translated into local languages, and the survey was conducted by a
trained nurse or an oncologist during routine medical visits. Data
collected from the survey were not verified with the patient medical
records. The first part of the survey included patient demographics
(age, education and place of residence) and the second part included
the circumstances in which BC signs or symptoms were first
presented to a medical doctor (MD), the type of signs or
symptoms of BC first noticed by the patient, additional signs or
symptoms detected by the patient before the first visit to an MD
and the time elapsed before examination by an MD for BC signs or
symptoms. Additional questions included the ownership status of
the medical unit where the patient was first seen by an MD (public
vs. private), factors potentially influencing the patient’s decision of
seeing an MD after the first signs or symptoms of BC and the time
elapsed from registering for the first medical examination due to BC
signs or symptoms to the start of therapy. Prevalence and availability
of mammography screening programmes were measured by two
variables on the questionnaire: reception of an invitation for a
free-of-charge mammography and participation in a free-of-charge
mammography. To achieve shorter interview times and alleviate
problems with non-responded items, a close-ended question
format with pre-defined answers was used instead of open-ended
questions (Appendix 1). In the subsequent analysis, the midpoints of
selected time categories were used to develop delay times and to
compute averages.
This survey did not fulfil the criteria of a medical experiment and
thus did not require ethics committee approval.
Outcome variables
The main outcome variables of the study included patient-related
delay time (PDT), system-related delay time (SDT) and total delay
time (TDT). PDT was defined as the time between the onset of first
symptoms and the first medical visit (this analysis included only
patients with self-detected cancers). SDT was the time between the
first medical visit and the start of therapy. TDT was determined
using eight individual scales, including one pertaining to PDT and
seven related to subsequent steps in a typical diagnostic process, and
was the sum of PDT and SDT (in patients with BC detected during a
medical visit or by mammography, PDT was considered zero). Each
scale contained eight categories identifying possible delay times
from ‘less than 1 week’ to ‘more than 12 weeks’. All time-
pertaining variables were continuous in nature. However, to
facilitate measuring process and increase reply rate, they were
structured as categorical characteristics. The resultant items
displayed the features of interval-type scales, and allowed calculating
arithmetic averages and performing expanded statistical analysis
including parametric tests and regression models.9
Statistical methods
The results were analysed using the Statistical Package for the Social
Sciences (SPSS, version 20). For continuous variables, data distribu-
tion was assessed visually (based on graphs) and by using the
common descriptive statistics including mean, standard error and
skewness coefficient. Some of the continuous variables (e.g. age,
PDT) were also presented as the interval, and not ordinal-scale
variables. The chi-square independence test, degrees of freedom
(df), P-value and value of Cramer’s V coefficient were used to
compare categorical variables, considering the country as a
separate variable. The PDT and SDT means in particular countries
were compared using one-way analysis of variance and post-hoc
tests (Games–Howell). If the distribution of a dependent variable
was strongly deviating from normal, logarithmic transformation
(log10) was performed.
Two separate multivariate linear regression analyses were
performed to create the best models for predicting PDT and SDT
values. The first step in the regression analysis was data preparation
that involved transforming several multicategory attributes into di-
chotomous variables (Appendix 2). The second step was a principal
component factor analysis of 14 items included in item Q.7 of the
questionnaire (statements that apply to feelings and behaviour from
the onset of BC symptoms until the final diagnosis). With factor
analysis, by extracting a set of more general, latent variables, we
reduced the number of items for measuring patients’ psychological
and behavioural circumstances from 14 to 5 (data available at
request). Multiple regression was first conducted in a stepwise
manner, using the Ordinary Least Squares method. This approach
allowed for the selection of a limited set of statistically significant
predictors out of variables found to be relevant in earlier analyses
(18 for PDT and 17 for SDT). To evaluate the impact of the country
on PDT and SDT, a multilevel analysis was performed.
These models were developed for the whole database and
separately for each country, and were presented as unstandardized
and standardized coefficients, t-values and p-values. The question-
naire used in India contained two items less in question Q.7, which
precluded calculation of scores for five psychological and behav-
ioural components extracted through factor analysis.
Results
Demographic characteristics
Due to the assistance of the trained medical personnel administering
the survey, virtually all questionnaires were adequately completed
and were eligible for analysis. No detailed data were collected on the
proportion of patients who refused participation in the survey, as
their number was considered negligible. A total of 6588 female BC
patients from 12 countries were surveyed (table 1). In most
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countries, the majority of patients were aged 40–69 years, with most
responders in the 50–59-year age category. There were substantial
differences between countries with regard to respondents’ education
level and place of residence (both P< 0.001).
BC detection
The highest proportion of patients with self-detected symptoms
were in Romania (93%) and Serbia (81%), and the lowest in
Hungary (48%) and Poland (56%) (figure 1). Countries with the
highest proportions of BC detected by mammography included
Hungary (35%) and Poland (34%). The circumstances in which
BC signs or symptoms were first noticed differed significantly
between particular countries (P< 0.001). The most common first
sign of BC detected by self-examination was a breast lump (>65%
in all countries). Less frequent symptoms included breast pain,
nipple or skin changes and nipple discharge (figure 2).
The availability of free mammography screening programmes
varied between countries (P< 0.001). Of 2218 patients who received
invitation for a mammography screening, 1015 (46%) actually
underwent the examination; 716 (32%) did not respond, as they
had already been examined within 2 years preceding the invitation
and 487 (22%) did not participate in the screening for other reasons.
Patient-related delay time
The respondents who had found BC signs or symptoms themselves
were inquired about the time elapsed from detecting the first sign or
symptom to receiving medical advice from an oncologist or another
MD. The mean PDT for all countries was 4.7 weeks, with a range
between 3.4 weeks in Hungary and 6.2 weeks in Latvia (table 2).
Based on the multivariate regression model, longer PDTs were
associated with patients’ distrust in the healthcare system and
successful therapy and with disregard or trivialization of
discovered symptoms. Overall, patients who regularly practiced
breast self-examination, experienced higher levels of fear of
disease, had at least a secondary education, were employed, were
influenced by family members or friends or lived in towns with a
population larger than 100 000 tended to have shorter PDT (table 3).
Other pertinent demographic characteristics such as age, education
and income level were also considered as potential independent
variables in the regression equation, but did not add considerably
to the predictive capacity of the model.
Multilevel regression analysis showed that among all predictors of
PDT, particular countries differed significantly with regard to the
impact of distrust, disregard and self-examination (chi-square,
reflecting change in 2 log likelihood from the baseline to the
outcome model, was 97.1; df = 4; P< 0.001). On the other hand,
the fixed term and some other predictors included in the
regression model (i.e. at least secondary education, living in a
town of more than 100 000 inhabitants, being employed, having
fear of disease and having support from family and friends) did
not show systematic inter-country variations.
To establish country-specific regression coefficients, multiple
regression equations were constructed for each country, and
proved to be significant, although at a different level of explained
variance in PDT (data not shown).
The results of country-specific regression models suggested that
the most universal predictors of PDT were distrust and disregard.
These factors were significant in all countries and almost always
most strongly affected PDT (the single exception was Lithuania,
where practicing breast self-examination was the strongest factor).
Other predictors identified in many countries were self-examination
and fear (data not shown). The countries with the highest regression
coefficients for distrust were Serbia (2.09), Romania (2.07) and
Table 1 The characteristics of the study participants
Countrya (n) BGR
(644)
HUN
(350)
IND
(268)
LVA
(156)
LTU
(458)
POL
(1000)
ROU
(319)
RUS
(1059)
SVK
(253)
SRB
(800)
TUR
(1031)
HRV
(250)
Total
(6588)
Contribution %b 9.8 5.3 4.1 2.4 7.0 15 4.8 16 3.8 12 16 3.8 100
Age (%)
<30 1.4 1.4 4.1 2.6 0.9 1.1 0.6 1.6 2.4 1.6 2.1 2.0 1.7
30–39 12.2 5.4 18.0 3.2 6.5 9.9 10.3 9.7 9.5 8.5 13.4 9.2 10.1
40–49 26.5 19.1 43.6 17.3 24.6 19.7 22.9 28.5 26.1 19.9 31.8 25.3 25.5
50–59 29.7 32.6 21.8 27.6 26.1 37.4 33.2 33.8 34.4 26.6 29.0 28.9 30.9
60–69 25.2 28.9 10.9 23.1 29.0 25.1 24.8 19.6 22.5 25.8 15.9 23.3 22.5
70 4.9 12.6 1.5 26.3 12.9 6.8 8.2 6.7 5.1 17.5 7.8 11.2 9.2
Education (%)
Primary 9.9 14.9 39.8 9.7 9.2 8.3 33.2 5.2 7.1 26.3 52.8 12.9 20.1
Technical secondary 25.0 21.4 29.9 5.2 28.9 16.7 18.2 13.2 16.6 8.2 2.5 49.2 16.3
Full secondary 28.5 40.3 23.4 45.8 34.0 48.8 32.6 40.8 42.7 40.1 23.6 14.9 35.7
Tertiary 36.5 23.4 6.9 39.4 27.9 26.2 16 40.7 33.6 25.4 21.1 23.0 27.9
Place of living (%)
Hamlet or village 11.0 13.7 31.9 18.2 20.1 20.8 14.7 15.3 26.4 24.8 5.5 17.3 16.8
Town <50K inhabitants 18.5 20.6 25.1 15.6 20.8 21.8 15.4 9.4 26.8 13.6 10.2 25.3 16.5
Town >50K–100K 21.2 28.9 17.5 27.3 9.9 14.2 20.1 6.7 22.4 17.9 8.5 13.7 14.7
Town >100K–500K 20.4 21.1 11.8 3.2 37.1 15.5 40.1 15.4 13.6 13.4 16.0 1.2 17.7
Town >500K 29.0 15.7 13.7 35.7 12.1 27.7 9.7 53.3 10.8 30.3 59.7 42.6 34.2
Getting an invitation to screening mammography (%)
Does not apply/no answer 41.9 38.6 58.2 39.7 30.8 45.7 98.1 34.3 39.1 100 55.1 30.8 52.2
Yes 10.7 43.7 1.1 44.2 27.7 54.3 1.9 19.9 38.7 – 9.0 42.8 22.4
No 47.4 17.7 40.7 16.0 41.5 – – 45.8 22.1 – 35.9 26.4 25.3
Participation in screening mammography (only patients who received invitation) (%)
Yes 46.4 83.7 33.3 62.8 81.9 21.6 12.2 64.6 85.1 – 72.0 59.2 45.8
No, mammography performed within the past 2 years 20.8 11.1 14.8 12.8 7.7 78.4 0.6 14.0 8.8 – 11.8 27.2 32.3
No, invitation or mammography not performed for
some other reason
32.8 5.2 51.9 24.4 10.3 – 87.1 21.4 6.1 – 16.1 13.6 22.0
a: Country: Bulgaria (BGR), Hungary (HUN), India (IND), Latvia (LVA), Lithuania (LTU), Poland (POL), Romania (ROU), Russia (RUS), Slovakia
(SVK), Serbia (SRB), Turkey (TUR) and Croatia (HRV).
b: Due to rounding of original figures to one decimal place, the sums of percentages may not add up to 100%.
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Figure 1 Circumstances of breast cancer detection
Figure 2 First symptoms of breast cancer noticed by patients
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Croatia (1.73). Disregard was the strongest predictor of delay in
Croatia (2.04), Latvia (1.72) and Slovakia (1.51), and the weakest
in Hungary (0.61) and Lithuania (0.86). Unexpectedly, the reversed
pattern of relationship was found in Romania (1.36), indicating
that a higher level of disregard and/or trivialization of discovered
symptoms corresponded with a shorter PDT. Practicing self-exam-
ination was the strongest factor related to shorter PDT in Lithuania
(1.31), Russia (1.14) and Slovakia (1.08), and the weakest in
Turkey (0.48) and Serbia (0.35). This factor was also an insig-
nificant element of the regression model in Latvia, Croatia, Romania
and Bulgaria.
System-related delay time
The mean SDT for all countries was 11.1 weeks, with the country-
specific means varying from 8.3 weeks for Lithuania to 24.7 weeks
for India (table 2).
In multiple regression analysis, the following variables were
correlated with shorter SDT: being diagnosed by an oncologist
versus another MD, having at least a secondary education, being
older than 60 years, having a family history of female cancers and
having a breast lump, as opposed to other symptoms. PDTs longer
than 4 weeks, higher levels of distrust in the healthcare system and
disregard for the diagnosis were the most strongly correlated with
longer SDT (table 4). Due to strong asymmetry of the output
variable and some problems with heteroscedasticity, logarithmic
transformation of original SDT values was performed to increase
reliability of confidence intervals and test results. The coefficients
presented in table 4 should be interpreted as exponents of 10 (base of
the transformation logarithm) and considered as factors by which
the length of SDT will change when the given predictor increases by
1 U (the results of these operations are shown in the last two
columns of table 4). Multilevel analysis showed differences
between particular countries regarding the correlations with a
PDT of >4 weeks, distrust in the healthcare system and disregard
of BC signs (2 = 300.6; df = 4; P< 0.001). The results of country-
specific regression models suggested that the most universal
predictors of SDT were distrust, disregard and PDT. PDT had the
highest impact on SDT in Croatia (0.50) and Romania (0.30), and
had no significant impact in Latvia, Lithuania and Slovakia.
Disregard was the strongest correlate of SDT in Bulgaria (0.07)
and Russia (0.06), with no significant correlation in Slovakia,
Latvia and Poland. Distrust was the most potent determinant of
SDT in Hungary (0.15) and Bulgaria (0.09), and had no considerable
effect in Slovakia, Romania, Serbia, Croatia and Turkey.
Table 2 Patient-related delay time (PDT), system-related delay time (SDT) and total delay time (TDT) by country (weeks)
Countrya N Mean PDT (SE) Skewness N Mean SDT (SE) Skewness N Mean TDT (SE) Skewness
BGR 448 4.83 (0.22) 0.82 644 12.51 (0.53) 2.91 644 15.87 (0.62) 2.66
HUN 167 3.44 (0.30) 1.56 350 14.47 (0.59) 1.96 350 16.12 (0.66) 2.06
IND 207 6.10 (0.33) 0.40 268 24.69 (1.22) 1.26 268 29.41 (1.37) 1.09
LVA 111 6.17 (0.47) 0.37 156 13.14 (0.72) 2.01 156 17.53 (0.89) 1.47
LTU 368 4.85 (0.25) 0.79 458 8.27 (0.37) 2.50 458 12.16 (0.45) 1.94
POL 557 3.61 (0.17) 1.42 1000 9.49 (0.22) 1.70 1000 11.50 (0.25) 1.58
ROU 271 6.02 (0.28) 0.30 319 20.42 (0.75) 1.11 319 25.54 (0.92) 0.89
RUS 718 4.81 (0.17) 0.84 1059 12.42 (0.37) 2.46 1059 15.68 (0.43) 2.14
SVK 154 4.00 (0.35) 1.14 253 10.72 (0.50) 1.83 253 13.15 (0.60) 1.80
SRB 663 4.47 (0.19) 0.89 800 9.16 (0.27) 2.20 800 12.86 (0.38) 1.56
TUR 694 4.84 (0.18) 0.81 1031 10.49 (0.32) 2.70 1031 13.75 (0.38) 2.40
HRV 167 4.88 (0.39) 0.73 248 10.23 (0.65) 2.33 248 13.51 (0.85) 2.03
Total 4525 4.71 (0.07) 0.84 6586 11.86 (0.14) 2.58 6586 15.10 (0.16) 2.27
a: Country: Bulgaria (BGR), Hungary (HUN), India (IND), Latvia (LVA), Lithuania (LTU), Poland (POL), Romania (ROU), Russia (RUS), Slovakia
(SVK), Serbia (SRB), Turkey (TUR) and Croatia (HRV).
SE, standard error.
Table 3 Factors influencing PDT (multivariate regression model)
Model Coefficientsa t Significant
Unstandardized
coefficients
Standardized
coefficients
B Standard
error
Betab
(Constant) 5.67 0.15 – 37.3 <0.001
Distrust 1.25 0.07 0.26 17.9 <0.001
Disregard 1.16 0.07 0.25 17.0 <0.001
Self-examination 0.63 0.07 0.13 8.9 <0.001
Fear 0.38 0.07 0.08 5.6 <0.001
Education level (at least secondary) 0.48 0.16 0.05 3.2 0.002
Job status (employed) 0.54 0.16 0.05 3.4 0.001
Support of family and friends 0.18 0.07 0.04 2.6 0.008
Place of living: >100 000 inhabitants 0.36 0.14 0.04 2.6 0.010
a: Dependent variable: Patient delay.
b: The absolute values of standardized betas indicate which predictors had the strongest impact on the
target variable; thus the most important variables are psychological and behavioural factors, including in
order of importance: DISTRUST, DISREGARD, SELF EXAMINATION and FEAR.
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TDT and its correlation with indicators of cancer
advancement
The mean TDT was 14.3 weeks, with a wide range from 11.5 weeks
in Poland to 29.4 weeks in India (P< 0.001; table 2). A strong asso-
ciation (P< 0.001) was found between TDT and indicators of cancer
advancement at diagnosis (tumour size, nodal spread and distant
metastases). The mean TDT in the subset of patients with breast
tumours of 2–4 cm and >4 cm was 15.5 and 20.1 weeks, respectively
(Supplementary table S1). Likewise, the mean TDT in patients with
and without nodal spread was 13.2 and 14.8 weeks, respectively, and
with and without distant metastases was, 18.3 and 14.2 weeks,
respectively.
Discussion
Several studies reported increased morbidity and mortality related to
delays in BC diagnosis and treatment.4–7 In a systematic review
including 87 studies (101 954 patients), delays in the range of 3–6
months between the onset of symptoms and the start of treatment
had a significantly adverse impact on survival.8 Our study, including
more than 6500 patients from 12 countries, is the largest single
analysis of factors influencing delay in diagnosis and treatment of
BC. Notably, the mean TDT in our study was 15 weeks, and only in
six countries, this period was shorter. We did not determine an
acceptable TDT, but clearly it should be kept to a minimum.
Indeed, in the current study, three indicators of tumour advance-
ment (tumour size, nodal involvement and dissemination) were
strongly associated with TDT.
In a group of 2212 Danish patients with various malignancies, BC
was among those with the shortest TDT (median 9.2 weeks).10 The
mean TDT of 14.3 weeks in our survey was longer than in the
aforementioned study, with a wide range between particular
countries. In a study including 100 patients with locally advanced
BC, the average time lapse before diagnosis was higher for rural
compared with urban patients (9.6 vs. 7.7 weeks, respectively).11
However, large differences between particular countries shown in
our study cannot be attributed to substantial distinctions in place
of residence and education level.12 In another recent study, 17% of
patients in the USA had a delayed BC diagnosis, defined as an
interval >3 months between the patient’s first breast-related
problem that prompted seeking of medical care and the BC
diagnosis.12 In that study, delayed BC diagnosis was associated
with younger age, minority race and self-identification of BC
symptoms compared with identification via an abnormal
mammogram, whereas women living with two or more household
members had lower odds of a delay in BC diagnosis. In our study,
factors influencing PDT, SDT and TDT were investigated separately;
however, in many countries, PDT significantly impacted TDT.
Nationwide screening mammography programmes allow
detection of early, non-palpable BC. The proportion of patients
with self-diagnosed symptoms of cancer may therefore be inversely
related to the prevalence and availability of mammography
screening. In our study, India, Romania and Serbia apparently did
not have such programmes available, and a small percentage of re-
spondents reporting otherwise may be ascribed to misunderstanding
the question. Of note, in our study, India and Romania had the
longest SDT and TDT.
In our study, the mean PDT for all countries was 4.7 weeks (3.4–
6.2 weeks). In a study from Malaysia, the median times to consult-
ation (corresponding respectively to PDT and TDT in our study)
were 2 and 5.5 months, respectively.13
In previous studies, the negative attitude toward BC treatment
was associated with delayed diagnosis,12 and increased levels of
fear with seeking cancer care earlier.14 Multivariate regression of
the current analysis indicated that distrust and disregard were the
most universal predictors of a longer PDT, whereas practicing breast
self-examination was associated with a shorter PDT. However, the
impact of distrust in the healthcare system and disregard of BC signs
on PDT was weak. Systematic approach and susceptibility to the
influence of authority may affect greater confidence in the
healthcare system, therefore causing fewer attempts to speed up
the procedure. Similarly, it cannot be excluded that a family that
calms the patient can reduce the level of determination. This result
may be the subject of further studies. Breast self-examination has
been shown to be ineffective as a screening tool.15,16 However, this
habit may be considered a surrogate of increased BC awareness and
thus might have positively impacted PDT in our study. Partridge et
al.17 indicated that older age is not an independent predictor of PDT
and is modestly associated with a more advanced stage of disease at
diagnosis.
The mean SDT in our study was 11.1 weeks and accounted for a
substantial part of the TDT. Delayed BC diagnosis and start of
treatment is influenced by patterns of healthcare utilization
and the effectiveness of primary care services. In the study by
Carter and Reilly,18 early-stage BC patients were three times more
likely to have received a clinical breast examination compared
with their locally advanced BC counterparts. Physician-related
delay in the diagnosis of BC is a common occurrence, and
Table 4 Factors influencing SDT (multivariate regression model)
Model Coefficientsa Significance tests Transformed B coefficients
Unstandardized coefficients Standardized
coefficients
t P-values 10^B Average % change in
SDT with 1 U change
in predictorB SE Beta
Intercept 0.85 0.03 33.3 <0.001 – –
PDT more vs. less than 4 weeks 0.15 0.01 0.21 12.8 <0.001 1.43 43%
Distrust 0.05 0.01 0.15 9.3 <0.001 1.13 13%
Oncologist vs. other MD 0.08 0.01 0.10 6.3 <0.001 0.82 18%
Ownership status of medical unit where patient was
first diagnosed (1-private; 2-public)
0.04 0.01 0.05 3.3 0.001 1.10 10%
Support of family and friends 0.02 0.01 0.04 2.8 0.005 1.04 4%
Disregard 0.02 0.01 0.04 2.7 0.006 1.04 4%
At least secondary education 0.03 0.01 0.05 2.9 0.004 0.92 8%
Age 60 years 0.04 0.01 0.05 3.0 0.003 0.92 8%
Self-examination 0.01 0.01 0.03 2.1 0.039 1.03 3%
Participation in mammography 0.04 0.02 0.03 2.0 0.042 1.08 8%
a: Dependent variable: Log 10 SDT.
PDT, patient delay time.
766 European Journal of Public Health
patients with normal mammograms are more likely to have longer
delay.19 In our study, the first examination being performed by an
oncologist, as compared with another MD, and being diagnosed in
a private, compared with public, unit were associated with
shorter SDT.
We are aware of some limitations of this study. First, our analysis
was based exclusively on the data collected from patient question-
naires, which were not verified with the patient medical records.
Thus, some information might have been imprecise. Second, the
survey was conducted by a trained medical personnel, thus the
anonymity of the answers was not maintained. In consequence,
the data provided might have been biased, for example due to a
shame on disclosure of all information, and this might have
differed in various cultural environments of particular countries.
We were also unable to verify the level of understanding of
particular questions and potential respective differences in
particular countries.
In conclusion, the delay in medical advice and diagnosis of BC
remains a serious problem. Several factors, mainly related to psy-
chological and behavioural patient attributes, appear to correlate
with delay in diagnosis and treatment of BC, but their impact
differs between particular countries. Other variables, for example
related to the differences in national healthcare systems (not
addressed in detail in this study), might also have a considerable
impact on the time to the initiation of BC therapy. Breast health
awareness and education may positively impact early detection,
diagnosis and treatment. The knowledge of these issues may allow
identifying groups of women with an increased risk of a delay and
building programmes that promote timely access to care. Clearly,
additional research considering specific socioeconomic and cultural
settings of particular populations may further elucidate this
question.
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Key points
 Psychological and behavioural patient attributes strongly
contribute to delays in BC diagnosis and treatment.
 The impact of these factors is significantly different in
particular countries.
 Identifying groups of women with an increased risk of delay
may allow designing preventive strategies.
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